KDR and cholangiocarcinoma: Overall, investigational targeted therapies for CCA encompass a diverse range of pathways, including p53/MDM2, ErbB, VEGFR/PDGFR, MET, ALK, MAPK, PI3K/AKT/mTOR, JAK/STAT, PARP, and KRAS signaling.